Header Logo

Connection

AARON THRIFT to Disease Progression

Back to Details
This is a "connection" page, showing publications AARON THRIFT has written about Disease Progression.
AARON THRIFT
Connection Strength
1.141
Disease Progression
  1. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies? Dig Dis Sci. 2021 06; 66(6):1965-1973.
    View in: PubMed
    Score: 0.414
  2. Differences in gene expression may contribute to the racial differences in the risk of MASLD. PLoS One. 2026; 21(5):e0345383.
    View in: PubMed
    Score: 0.154
  3. Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma. Minerva Gastroenterol (Torino). 2024 Dec; 70(4):454-462.
    View in: PubMed
    Score: 0.135
  4. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.080
  5. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Gastroenterol. 2016 07; 32(4):319-24.
    View in: PubMed
    Score: 0.078
  6. AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus. Gastroenterology. 2025 Nov; 169(6):1184-1231.
    View in: PubMed
    Score: 0.037
  7. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.036
  8. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.035
  9. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.029
  10. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.027
  11. Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study. Dig Dis Sci. 2020 10; 65(10):2992-2999.
    View in: PubMed
    Score: 0.025
  12. Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):427-433.
    View in: PubMed
    Score: 0.025
  13. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia. Aliment Pharmacol Ther. 2019 05; 49(10):1274-1281.
    View in: PubMed
    Score: 0.024
  14. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018 08; 155(2):316-326.e6.
    View in: PubMed
    Score: 0.022
  15. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.